From Innovation To Transformation
Pioneering Precision in Ophthalmic Care
Since our inception in 2015, Seinda Biomedical Corp. has been at the forefront of revolutionizing eye health. By uniting experts from biomedical, pharmaceutical, immunology, and ophthalmology disciplines, we've cultivated a multidisciplinary approach to address the complexities of ocular diseases.
Innovative Diagnostics and Therapeutics
Our proprietary i-ImmunDx™ platform exemplifies our commitment to innovation, offering point-of-care diagnostic solutions that are both accurate and user-friendly. These tools empower clinicians to make informed decisions swiftly, enhancing patient outcomes. On the therapeutic front, our lead candidate, SY-201, a novel small peptide treatment for dry eye disease, has shown promising results in Phase 2 clinical trials in the U.S., with Phase 3 trials underway in both the U.S. and China.
State-of-the-Art Facilities
Located on Guangzhou International Bio-Island in China, our R&D and production base boasts GMP-compliant manufacturing capabilities, including ISO class 8 clean production workshops and ISO class 7 laboratories. This infrastructure ensures the highest standards in our product development and manufacturing processes.
A Vision for Global Eye Health
At Seinda, our mission is clear: to bring excellence and precision to ophthalmology by providing improved diagnostic and therapeutic choices for eye care. Through continuous research, collaboration, and a patient-centric approach, we aim to address unmet needs in ocular health and enhance the quality of life for individuals worldwide.
Biomarker
Foundations for Precision Diagnosis and Treatment
We harness our deep expertise in the molecular underpinnings of ophthalmic disorders to identify and validate key biomarkers. These insights drive the development of targeted diagnostics and therapeutics--bridging science and care through precision.
Diagnostics
Mechanism-Driven, Biomarker-Based Tear Testing
Grounded in our deep understanding of ocular disease mechanisms, we develop point-of-care diagnostics that measure disease-specific biomarkers in tear fluid. Our i-ImmunDX™ platform enables fast, non-invasive testing, bringing molecular precision to everyday clinical decision-making.
Therapeutics
Next-Generation Treatments with Targeted Action
Our therapeutic programs focus on novel molecules that directly address the underlying drivers of disease. With candidates like SY-201 for dry eye, we aim to deliver safer, more effective treatments that move beyond symptom relief to meaningful clinical impact.
Envisioning Better Health
Biomarker-based Diagnostic
Designed For Ophthalmic Precision Medicine
i-ImmunDx™ Platform
From Detection to Direction
Our tear-based diagnostic tests go beyond detection, they accurately identify disease presence, discriminate between subtypes, and assess severity. These insights guide clinicians in designing the most effective, personalized treatment strategies for each patient.
Therapeutic Solution
SY-201 – Redefining Dry Eye Treatment
SY-201 is a next-generation treatment for dry eye disease, designed to restore the ocular surface by targeting core disease mechanisms. With a novel multi-modal action, it delivers fast, effective relief—without the stinging, blurriness, or discomfort common in existing therapies. This twice-daily, preservative-free formulation is safe for contact lens users and enhances patient comfort, adherence, and outcomes.
